文献速递心脑血管急症

美国急性冠脉综合征患者经皮冠状动脉介入治疗后的抗血小板治疗临床动态评估

Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.
PubMed 文献 · JAMA Netw Open · 2023-04-03
一句话结论美国2010-2019年ACS-PCI后初始P2Y12抑制剂由氯吡格雷向普拉格雷/替格瑞洛大幅转变,降级治疗增加,基线出血风险与初始选择相关但与降级关联有限。

该回顾性队列研究利用2010—2019年MarketScan商业理赔数据,纳入62423例因ACS行PCI且出院后30天内启用P2Y12抑制剂的患者,描述初始P2Y12抑制剂选择与切换的长期趋势及决定因素。结果显示初始氯吡格雷使用从2010年77.5%降至2019年29.6%,普拉格雷或替格瑞洛从22.5%升至60.4%;PCI后1年内11.0%患者切换治疗,多为降级,降级比例从2010年1.8%升至2018年12.6%。2016—2018年22886例中8588例(37.5%)存在基线大出血风险,其降低普拉格雷或替格瑞洛初始选择(aOR 0.78;95%CI 0.74-0.84);11285例启用普拉格雷或替格瑞洛者中,基线大出血风险(aHR 1.11;95%CI 1.00-1.23)与随访期出血(aHR 4.42;95%CI 3.62-5.93)与降级相关。

要点

  • 2010—2019年62423例ACS-PCI后启用P2Y12抑制剂患者中,初始氯吡格雷从77.5%降至29.6%,普拉格雷或替格瑞洛从22.5%升至60.4%。
  • PCI后1年内11.0%患者切换P2Y12抑制剂,主要为降级;降级比例从2010年1.8%升至2018年12.6%。
  • 2016—2018年22886例中8588例(37.5%)有基线大出血风险,其降低普拉格雷或替格瑞洛初始选择(aOR 0.78;95%CI 0.74-0.84)。
  • 11285例启用普拉格雷或替格瑞洛者中,基线大出血风险(aHR 1.11;95%CI 1.00-1.23)和随访期出血(aHR 4.42;95%CI 3.62-5.93)与降级相关。
  • 作者认为更有效P2Y12抑制剂使用增加,强调需优化以患者为中心的治疗策略,在维持最佳抗血小板活性的同时降低PCI后亚急性期出血风险。

适用人群与场景

  • 2010—2019年MarketScan商业理赔数据中年龄18岁及以上、因ACS行PCI、过去1年未使用P2Y12抑制剂、且在PCI住院出院后30天内填写P2Y12抑制剂处方的患者。

诊断标准与关键阈值

  • 基线大出血风险采用学术研究联合会高出血风险(Academic Research Consortium for High Bleeding Risk)标准衡量。
  • 降级定义为从普拉格雷或替格瑞洛切换至氯吡格雷。

研究设计与关键结果

  • 回顾性队列研究,纳入62423例启用P2Y12抑制剂患者(女性22.4%,男性77.6%;平均[SD]年龄54.32[7.13]岁)。
  • 初始氯吡格雷使用从2010年77.5%降至2019年29.6%,初始普拉格雷或替格瑞洛从22.5%升至60.4%。
  • PCI后1年内11.0%患者切换治疗,主要为降级;降级比例从2010年1.8%升至2018年12.6%。
  • 2016—2018年22886例中8588例(37.5%)存在基线大出血风险,其降低普拉格雷或替格瑞洛初始选择(aOR 0.78;95%CI 0.74-0.84)。
  • 11285例启用普拉格雷或替格瑞洛者中,基线大出血风险(aHR 1.11;95%CI 1.00-1.23)和随访期出血(aHR 4.42;95%CI 3.62-5.93)与降级相关。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,更有效P2Y12抑制剂使用增加,强调有机会优化以患者为中心的治疗策略,在维持最佳抗血小板活性的同时降低ACS-PCI后亚急性期出血风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: A platelet ADP P2Y12 receptor (P2Y12) inhibitor plus aspirin is standard therapy for patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Compared with clopidogrel, prasugrel and ticagrelor are associated with superior antiatherothrombotic effects but increased bleeding risk; with recent guideline updates, it is important to describe current treatment patterns and the role of bleeding risk in treatment choice.

OBJECTIVE: To describe secular trends and determinants of initial P2Y12 inhibitor choice and switching, including deescalation (switch from prasugrel or ticagrelor to clopidogrel).

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used MarketScan Commercial Claims Data from 2010 to 2019 for patients aged 18 years or older who underwent PCI for ACS, had no P2Y12 inhibitor use in the past year, and filled a P2Y12 inhibitor prescription within 30 days after PCI hospitalization discharge. Data were analyzed from February to May 2022.

EXPOSURES: Clopidogrel, prasugrel, and ticagrelor, with determinants including bleeding risk measured using Academic Research Consortium for High Bleeding Risk criteria, sociodemographic characteristics, P2Y12 inhibitor copays, and bleeding events during follow-up.

MAIN OUTCOMES AND MEASURES: The prevalence of each P2Y12 inhibitor among patients who initiated the drugs and the prevalence of switching within 12 months after PCI were evaluated. The association between baseline bleeding risk and bleeding manifestations during follow-up and initial treatment and deescalation were calculated using multivariable logistic and Cox proportional hazards regression models.

RESULTS: Between 2010 and 2019, 62 423 patients were identified who initiated P2Y12 inhibitors (females, 22.4%; males, 77.6%; mean [SD] age, 54.32 [7.13] years). The prevalence of clopidogrel as initial therapy decreased from 77.5% in 2010 to 29.6% in 2019, while initial use of prasugrel or ticagrelor increased from 22.5% to 60.4%. Within 1 year after PCI, 11.0% of patients switched therapy, mostly for deescalation. Deescalation prevalence increased from 1.8% in 2010 to 12.6% in 2018. Between 2016 and 2018, 8588 of 22 886 (37.5%) patients had major baseline bleeding risk, which decreased the selection of prasugrel or ticagrelor as initial therapy (adjusted odds ratio, 0.78; 95% CI, 0.74-0.84). Among 11 285 patients who initiated prasugrel or ticagrelor, major bleeding risk at baseline (adjusted hazard ratio, 1.11; 95% CI, 1.00-1.23) and the occurrence of bleeding during follow-up (adjusted hazard ratio, 4.42; 95% CI, 3.62-5.93) were associated with deescalation.

CONCLUSIONS AND RELEVANCE: A strong shift in preference for prasugrel and ticagrelor as initial therapy following PCI for ACS was observed. Deescalation increased over the study period. Major bleeding risk at baseline was moderately associated with initial treatment choice but had a limited association with deescalation. The increasing use of more potent P2Y12 inhibitors emphasizes opportunities to enhance preemptive patient-centered treatment strategies to maintain optimal antiplatelet activity while reducing bleeding risk during the subacute period following PCI for ACS.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Wang Y, Cavallari LH, Brown JD, et al. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US. JAMA Netw Open. 2023. PMID: 37067798. doi:10.1001/jamanetworkopen.2023.8585

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。